These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31881245)

  • 1. Lyn regulates creatine uptake in an imatinib-resistant CML cell line.
    Okumu DO; Aponte-Collazo LJ; Dewar BJ; Cox NJ; East MP; Tech K; McDonald IM; Tikunov AP; Holmuhamedov E; Macdonald JM; Graves LM
    Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129507. PubMed ID: 31881245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn.
    Ito T; Tanaka H; Kimura A
    Eur J Haematol; 2007 May; 78(5):417-31. PubMed ID: 17432977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia.
    Zimmerman EI; Dollins CM; Crawford M; Grant S; Nana-Sinkam SP; Richards KL; Hammond SM; Graves LM
    Mol Pharmacol; 2010 Nov; 78(5):811-7. PubMed ID: 20693279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BIRC6 mediates imatinib resistance independently of Mcl-1.
    Okumu DO; East MP; Levine M; Herring LE; Zhang R; Gilbert TSK; Litchfield DW; Zhang Y; Graves LM
    PLoS One; 2017; 12(5):e0177871. PubMed ID: 28520795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia.
    Cooper MJ; Cox NJ; Zimmerman EI; Dewar BJ; Duncan JS; Whittle MC; Nguyen TA; Jones LS; Ghose Roy S; Smalley DM; Kuan PF; Richards KL; Christopherson RI; Jin J; Frye SV; Johnson GL; Baldwin AS; Graves LM
    PLoS One; 2013; 8(6):e66755. PubMed ID: 23826126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicolor monitoring of dysregulated protein kinases in chronic myelogenous leukemia.
    Wang Q; Zimmerman EI; Toutchkine A; Martin TD; Graves LM; Lawrence DS
    ACS Chem Biol; 2010 Sep; 5(9):887-95. PubMed ID: 20583816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel co-operative mechanism linking TGFβ and Lyn kinase activation to imatinib resistance in chronic myeloid leukaemia cells.
    Smith PG; Tanaka H; Chantry A
    Oncotarget; 2012 May; 3(5):518-24. PubMed ID: 22643838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
    Yandim MK; Ceylan C; Elmas E; Baran Y
    Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-time analysis of imatinib- and dasatinib-induced effects on chronic myelogenous leukemia cell interaction with fibronectin.
    Obr A; Röselová P; Grebeňová D; Kuželová K
    PLoS One; 2014; 9(9):e107367. PubMed ID: 25198091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
    Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
    Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
    Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
    Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
    Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
    Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of Lyn kinase in imatinib-resistant chronic myelogenous leukemia].
    Liu J; Zhao XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1352-5. PubMed ID: 23257431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.
    Donato NJ; Wu JY; Stapley J; Gallick G; Lin H; Arlinghaus R; Talpaz M
    Blood; 2003 Jan; 101(2):690-8. PubMed ID: 12509383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts.
    Tabe Y; Jin L; Iwabuchi K; Wang RY; Ichikawa N; Miida T; Cortes J; Andreeff M; Konopleva M
    Leukemia; 2012 May; 26(5):883-92. PubMed ID: 22005789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
    Dai Y; Rahmani M; Corey SJ; Dent P; Grant S
    J Biol Chem; 2004 Aug; 279(33):34227-39. PubMed ID: 15175350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
    Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
    Dai Y; Rahmani M; Pei XY; Dent P; Grant S
    Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.